Myosin Therapeutics Invites Investors at BioFuture 2026

JUPITER, Fla., Oct. 16, 2026 /CourierPR/ -- Myosin Therapeutics, a biotechnology company based in Jupiter, Florida, has been selected as a 2026-2027 National Cancer Institute (NCI) SBIR Investor Initiatives Showcase Company. This recognition has led to an invitation for the company to present at BioFuture 2026, an event scheduled for October 27-28 in New York City.

The panel will feature biotechnology leaders discussing emerging approaches in oncology, including next-generation cell therapies, AI-enabled cancer drug discovery, precision medicines, and advanced therapeutic platforms. Dr. Miller will be joined by Karen Smith, MD, PhD, MBA, LLM, the Chief Medical Officer, for investor and strategic partner meetings throughout the conference.

Myosin Therapeutics is advancing MT-125, a first-in-class non-muscle myosin inhibitor designed to disrupt fundamental mechanical dependencies of cancer cells, leading to tumor cell death. The company's science is supported by two peer-reviewed publications in Cell. MT-125 has received FDA Orphan Drug Designation for malignant gliomas and FDA Fast Track Designation for glioblastoma (GBM). The NCI-supported STAR-GBM trial (NCT07185880) is enrolling patients with newly diagnosed, MGMT unmethylated GBM at Mayo Clinic sites in Florida, Arizona, and Minnesota.

The BioFuture conference, produced by Demy-Colton, is a healthcare and technology event where innovators and investors come together to shape the future of biopharma. The 2026 meeting, held in New York City, brings together 500+ global attendees and 100+ speakers, with 50+ presenting companies featured in its Therapeutic Spotlight Panels and Seed Showcase. Myosin Therapeutics is one of the companies that will be spotlighted during the event.

With the STAR-GBM trial advancing toward its Phase 2 dose expansion stage, BioFuture comes at the right time to meet the investors and pharmaceutical partners who can help support Myosin Therapeutics' planned extension of MT-125 into two additional treatment-resistant cancers.

The company is also looking to extend the use of MT-125 into other aggressive cancers, leveraging its unique approach to target the physical mechanics of tumor cells. Myosin Therapeutics believes that this non-muscle myosin inhibitor can offer a novel treatment strategy that complements existing therapies and addresses the limitations of current approaches.

Myosin Therapeutics' participation in BioFuture 2026 is a significant milestone in the company's journey to develop innovative cancer treatments. The conference provides an opportunity for the company to showcase its progress and engage with potential partners and investors who can support its mission to improve cancer treatment outcomes.